Creative Planning Fate Therapeutics Inc Transaction History

Creative Planning

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 04, 2021	SELL	$67.25 - $92.52 $280,768 - $386,271	-4,175 Closed	0 $0
Q1 2021 Apr 30, 2021	SELL	$72.16 - $117.4 $142,227 - $231,395	-1,971 Reduced 32.07%	4,175 $344,000
Q4 2020 Jan 29, 2021	SELL	$38.09 - $100.95 $22,396 - $59,358	-588 Reduced 8.73%	6,146 $559,000
Q3 2020 Nov 05, 2020	SELL	$30.41 - $40.5 $29,893 - $39,811	-983 Reduced 12.74%	6,734 $269,000
Q2 2020 Jul 23, 2020	BUY	$20.21 - $35.23 $155,960 - $271,869	7,717 New	7,717 $265,000
Q1 2019 Apr 24, 2019	SELL	$13.15 - $18.71 $144,347 - $205,379	-10,977 Closed	0 $0
Q4 2018 Feb 01, 2019	BUY	$11.48 - $16.98 $126,015 - $186,389	10,977 New	10,977 $141,000
Q4 2017 Jan 17, 2018	SELL	$3.94 - $6.64 $110,320 - $185,920	-28,000 Closed	0 $0
Q3 2017 Oct 17, 2017	BUY	$2.6 - $4.31 $72,800 - $120,679	28,000	28,000 $111,000

167

108M

79.2K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $138M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.